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Abstract
Background: Rothia mucilaginosa is a Gram-positive bacterium occurring as a commensal in the oral cavity and
upper respiratory tract. Although rarely pathogenic in an immunocompetent host, it can cause severe opportunistic
infections in immunocompromised individuals.
Case presentation: A 67-year-old white woman had a routine blood analysis before undergoing knee surgery. The
results showed leukopenia for which bone marrow examination was performed, showing an underlying acute
myeloid leukemia. During the neutropenic phase after a second induction with cytarabine/idarubicin, she
developed fever, headaches, and photophobia. Cultures of cerebrospinal fluid were positive for Rothia mucilaginosa.
Despite full therapy with antibiotics, neurosurgical interventions, and intensive care support, our patient died due to
refractory intracranial hypertension and transtentorial herniation.
Conclusions: Meningitis due to Rothia mucilaginosa is a rare but potentially lethal infection in patients with
neutropenia, and evidence-based guidelines for the treatment of this disease are lacking. We suggest an empirical
therapy with amoxicillin/rifampicin until adjustments can be made based on an antibiogram. Intrathecal or
intraventricular administration of antibiotics can be considered if neurosurgical access is already obtained because
of disease-associated complications.
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Background
Opportunistic infections are a major cause of morbidity
and mortality in patients going through a neutropenic
phase following chemotherapy or bone marrow trans-
plantation as a treatment for acute myeloid leukemia
(AML) [1]. Rothia mucilaginosa is a Gram-positive bac-
terium that occurs as a commensal in the oral cavity and
upper respiratory tract. However, in the context of neu-
tropenia, this bacterium causes invasive infections such
as bacteremia, endocarditis, peritonitis, pneumonia, for-
eign body infections, and meningitis [2]. However, be-
cause of its rarity as an invasive pathogen, there is little
literature on Rothia mucilaginosa. The literature on
meningitis caused by this bacterium is limited to a few
case descriptions almost exclusively within a pediatric
population [1–3]. Here we present an adult patient with
neutropenia who developed meningitis with Rothia
mucilaginosa, showing insufficient response to therapy
and further clinical deterioration after admission to our
intensive care unit. We hope other clinicians can use
this article as a guideline when they are confronted with
Rothia mucilaginosa meningitis.
Case presentation
Our patient was a 67-year-old white woman with no
relevant medical history. She was on no medication at
time of admission. She did not smoke tobacco and con-
sumed no alcohol. She was retired at time of admission
and worked as a librarian before. She was married and
had two children, both healthy. Her mother was
88-years old and still alive; her father died at the age of
94, cause not known. None of them had malignancies in
their past. At time of admission she felt perfectly nor-
mal, had no B-symptoms, no bleedings, and no signs of
infections. She was 152 cm in height and weighed 72 kg,
with a body surface area of 1.7 m2. Her temperature was
36.7 °C (98 °F), blood pressure 128/79 mmHg, and pulse
73 beats per minute. No cardiac, respiratory, gastrointes-
tinal, urological, dental, or neurological anomalies were
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Fig. 1 Peripheral blood count at time of diagnosis. ANC: absolute neutrophil count, MCH: mean corpuscular hemoglobin, MCHC: mean corpuscular
hemoglobin concentration, MCV: mean corpuscular volume, WBC: white blood cells. Translations: absolute neutrofielen telling: absolute neutrophil
count, basofiele granulocyten: basophils, blasten: blasts, bloedplaatjes: platelets, commentaar plaatjes: comment platelets, differentiatie: differentiation,
eenheid: unit, eosinofiele granulocyten: eosinophils, hematocriet: hematocrit, hemoglobine: hemoglobin, hypochromie: hypochromia, lymfocyten:
lymphocytes, microscopische: microscopic, monocyten: monocytes, neutrofiele granulocyten: neutrophils, normoblasten: normoblasts, perifeer bloed:
peripheral blood, polychromasie: polychromasia, refwaarde: reference interval, resultaat: result, reuze: giant, rode bloedcellen: red blood cells, stopgezet:
stopped, uitzicht serum/plasma: sight serum/plasma, witte bloedcellen: white blood cells
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detected at physical examination. The reason for her ad-
mission at our Hematology department was a routine
blood analysis, performed before undergoing knee sur-
gery, which showed leukopenia (Fig. 1). A bone marrow
examination was performed, revealing an underlying
AML (Table 1 and Fig. 2).
Induction therapy with cytarabine (200 mg/m2, con-
tinuous infusion over 24 hours, on days 1–7) and idaru-
bicin (12 mg/m2, once daily, infusion over 1 hour, on
days 1–3) was initiated, and given her neutropenic con-
dition from the start, she stayed in protective isolation at
the Hematology department. She received levofloxacin
500 mg once daily for intestinal decontamination and in-
fectious prophylaxis. Since no complications occurred,
the second induction was initiated with cytarabine
(1000 mg/m2, twice daily, infusion over 3 hours, on days
1–3) and idarubicin (12 mg/m2, once daily, infusion over
1 hour, on days 3–5). After this therapy, she developed
general weakness and diarrhea. At day 35 after the first
induction, she developed neutropenic fever for which
ceftazidime (2000 mg intravenously every 8 hours, con-
tinuous infusion over 8 hours) and Colimycin (colisti-
methate sodium; 2 × 106 international units
intravenously every 6 hours) were started, guided by the
presence of a resistant Pseudomonas aeruginosa strain in
the fecal cultures. Two days later she started vomiting
and reported headaches and photophobia. Analysis of
her cerebrospinal fluid (CSF) was compatible with bac-
terial meningitis (Table 2). She was transferred to our in-
tensive care unit receiving empirical antibiotic therapy
with ceftazidime, Colimycin (colistimethate sodium),
amoxicillin (2000 mg intravenously every 4 hours), and
vancomycin (loading dose 1400 mg intravenously over 2
hours, maintenance dose 2500mg intravenously over 24
hours); although the plasma concentration of this last
one only reached therapeutic levels after 2 days. Gram
Table 1 Subtype of leukemia
Cytomorphology 75% blasts, no Auer rods




Conclusion AML, favorable risk [9]
AML acute myeloid leukemia
Fig. 2 Microscopy of bone marrow aspirate. Because of peripheral blood admixture only peripheral blood cells can be seen. The colored cells
are myeloblasts
Clauwaert et al. Journal of Medical Case Reports           (2019) 13:84 Page 3 of 6
staining on the CSF showed Gram-positive cocci, which
were presumed to represent Staphylococci at first. How-
ever, cultures identified Rothia mucilaginosa as the re-
sponsible pathogen and after 2 days of empirical
therapy, antibiotics were switched to amoxicillin (2000
mg intravenously every 4 hours) and rifampicin (600 mg
intravenously every 12 hours) bi-therapy based on an
antibiogram (Fig. 3) and the (limited) available literature
[1, 2, 4, 5]. Blood cultures remained negative. She was
stable for 1 week until she developed significant lethargy
and anisocoria. Hydrocephalus was diagnosed with com-
puted tomography (CT) imaging for which external ven-
tricular drainage was provided. Because of a
non-communicating hydrocephalus due to ventriculi-
tis, a second drainage was performed. In spite of this,
our patient developed bilateral mydriasis without
reactivity to light and increasing edema on brain CT,
leading to the placement of two more external ventri-
culostomies in the temporal horns (Fig. 4). Despite
these neurosurgical interventions and medical therapy
with hypertonic salt and mannitol, intracranial pres-
sure continued to rise, resulting in progressive brain
edema and transtentorial herniation. In consultation
with her family, further therapy was discontinued and
she died on day 49 after the first induction chemo-
therapy. An autopsy was considered, but, given the
clear medical context, this would not have led to
other conclusions (Additional file 1).
Discussion
The fight against aggressive forms of leukemia such as
AML, does not only consist of eradicating the malignant
cells, but also requires effective treatment of potentially
lethal complications of the disease and its antineoplastic
therapy. These complications include mainly infectious
episodes resulting from the destruction of the immune
system [6]. We presented a case of a 67-year-old patient
who was diagnosed as having AML and died of an op-
portunistic infection despite obtaining a molecular re-
mission after the second induction course with
chemotherapy. More specifically, she developed
Table 2 Analysis of the cerebrospinal fluid at time of diagnosis
Result Reference interval
Glucose (mg/dL) 15.7 49–80
Protein (mg/dL) 77.4 15–50
Lactate (mg/dL) 92.2 10–22
Leukocytes (/μL) 132 < 10
Erythrocytes (/μL) 14.7 0
Fig. 3 Antibiogram of Rothia mucilaginosa at time of diagnosis. IV intravenous
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meningitis with Rothia mucilaginosa, a condition of
which little is known and only a few case reports are
available and most of them in a pediatric population.
We proposed a way to treat this condition because
evidence-based guidelines are lacking.
Rothia mucilaginosa is a commensal Gram-positive
bacterium in the oral cavity and upper respiratory tract. In
an immunocompetent host it has low virulence, but it can
behave as an opportunistic pathogen in the presence of
favorable host factors [2]. Chemotherapy in the treatment
of AML not only induces long-term neutropenia, but also
extensive mucositis and it requires a central catheter: all
these facilitate the invasive character of a germ. In addition,
repeated or prolonged exposure to prophylactic or thera-
peutic broad-spectrum antibiotics may lead to the selection
of pathogenic germs [1]. More specifically, a significant
association was seen between Rothia bacteremia and the
use of fluoroquinolones [7]. In our patient, levofloxacin for
intestinal decontamination was provided at the start of
induction. Although blood cultures remained negative in
this case, hematogenous dissemination is assumed.
Diagnosis of meningitis in patients with neutropenia can
be delayed because of less pronounced symptomatology as
a result of agranulocytosis. In addition, antimicrobial
agents penetrate the blood–brain barrier less since there is
little or no meningeal inflammation. Because meningitis
due to Rothia mucilaginosa is rare and only a few cases in
an adult population have been described, it was difficult to
choose the most adequate therapy. Selection of the antibi-
otics could be based on the cultures obtained by lumbar
puncture. Taking into account the penetration of the
agents into the CSF and recommendations from previous
case reports, a combination antibiotherapy with amoxicil-
lin and rifampicin was given. Vancomycin had been the
first choice in the majority of case reports [1], but a higher
minimum inhibitory concentration (MIC) was reported by
the laboratory compared to amoxicillin (1 μg/mL versus
0.064 μg/mL). In addition, the penetration of vancomycin
in the CSF is thought to be low because of its hydrophilic
nature and high molecular weight, although recent re-
search could not confirm this [8]. The question of whether
there is additional benefit of intrathecally administered an-
tibiotics is at present unanswered. Given the need for
neurosurgical intervention to achieve this, this is, in gen-
eral, discouraged and only considered when disease com-
plications necessitate a ventricular drainage [1, 4, 5].
However, in our patient, despite the surgical intervention,
no intraventricular antibiotics were administered since
analysis of the perioperative CSF showed decreasing white
blood cell counts as compared to the result at diagnosis,
and because of the absence of bacteria on microscopic
evaluation. Furthermore, the rapidly declining medical
condition of our patient did not allow us to consider any
additional intracerebral manipulation.
Fig. 4 a Brain computed tomography at time of diagnosis, without particular complications. b Supratentorial hydrocephalus with loss of gyri. c
Placement of ventriculostomies (bilateral, cannot be seen on the image) with reduction of the volume of the ventricular system. d
Ventriculostomies in situ, although further development of edema and cerebellar herniation
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Conclusions
Rothia mucilaginosa meningitis is a rather rare compli-
cation with a high mortality risk in patients with neutro-
penia. The lack of therapeutic guidelines makes it
difficult to maintain evidence-based medicine. Empirical
therapy with amoxicillin/rifampicin may be a reasonable
initial choice until adjustments can be made based on
the antibiogram. Intrathecal or intraventricular adminis-
tration of antibiotics may be considered if neurosurgical
access is already obtained because of disease-associated
complications.
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